CYTライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (16 3月 2024 @ 05:00):

Stats
本日の出来高	1.01M
平均出来高	167 616
時価総額	108.71M
EPS	$0 ( 2024-03-28 )
Last Dividend	$0.130 ( 2015-11-06 )
Next Dividend	$0 ( N/A )
P/E	-3.25
ATR14	$0.0570 (1.89%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-20	Leonard Braden Michael	Buy	170 589	Common Stock, par value $0.001 per share
2024-03-18	Leonard Braden Michael	Buy	113 777	Common Stock, par value $0.001 per share
2024-03-15	Leonard Braden Michael	Buy	0	Common Stock, par value $0.001 per share
2024-03-15	Leonard Braden Michael	Sell	0	Common Stock, par value $0.001 per share
2024-03-04	Gaiero David G	Buy	2 373	Common Stock

INSIDER POWER
11.39
Last 95 transactions
Buy: 1 923 587 \| Sell: 1 715 632

ボリューム相関

長: -0.03 (neutral)

短: 0.00 (neutral)

Signal:(42.394) Neutral

Cyteir Therapeutics, Inc. 相関

10 最も正の相関
EBACU	0.891
TCMD	0.875
ECHO	0.873
TZPSU	0.872
WULF	0.871
TZPS	0.869
JNCE	0.869
MBTCU	0.868
RBNC	0.866
NLTX	0.865

10 最も負の相関
VIASP	-0.896
STBA	-0.894
CMBM	-0.893
FBNC	-0.893
MMAC	-0.893
TRST	-0.892
LSAQ	-0.891
CVCY	-0.891
OPI	-0.891
VGFC	-0.891

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Cyteir Therapeutics, Inc. 相関 - 通貨/商品

-0.56
( weak negative )

-0.64
( weak negative )

0.00
( neutral )

-0.80
( strong negative )

-0.93
( very strong negative )

0.48
( neutral )

Cyteir Therapeutics, Inc. 財務諸表

Annual	2022
収益:	$0
総利益:	$-1.38M (0.00 %)
EPS:	$-1.250

FY	2022
収益:	$0
総利益:	$-1.38M (0.00 %)
EPS:	$-1.250

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.201

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.070

Financial Reports:

No articles found.

Cyteir Therapeutics, Inc. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Cyteir Therapeutics, Inc. Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A

Information

First Dividend	$0.0100	2009-08-06
Last Dividend	$0.130	2015-11-06
Next Dividend	$0	N/A
Payout Date	2015-11-25
Next Payout Date	N/A
# dividends	26	--
Total Paid Out	$2.66	--
Avg. Dividend % Per Year	0.00%	--
Score	1.76	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-06-20)

$0 Estimate 0.00 %

Dividend Stability

0.09 Very Bad

Dividend Score

1.76

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2009	$0	0.00%
2010	$0	0.00%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0	1.500	0	0	[0 - 0.5]
returnOnAssetsTTM	-0.236	1.200	-7.86	-9.43	[0 - 0.3]
returnOnEquityTTM	-0.231	1.500	-3.68	-5.52	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	21.89	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	21.66	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	21.65	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.000122	-1.500	10.00	-10.00	[0 - 0.6]
interestCoverageTTM	39.40	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.716	2.00	-0.239	-0.477	[0 - 30]
freeCashFlowPerShareTTM	-0.724	2.00	-0.362	-0.724	[0 - 20]
debtEquityRatioTTM	0.000128	-1.500	10.00	-10.00	[0 - 2.5]
grossProfitMarginTTM	0	1.000	-3.33	-3.33	[0.2 - 0.8]
operatingProfitMarginTTM	0	1.000	-2.00	-2.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-1 611.81	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				2.08

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-3.52	1.000	-0.457	0	[1 - 100]
returnOnEquityTTM	-0.231	2.50	-2.37	-5.52	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.724	2.00	-0.241	-0.724	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.716	2.00	-0.239	-0.477	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0	1.000	-2.50	0	[0.1 - 0.5]
Total Score				-0.983

Cyteir Therapeutics, Inc.

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.